T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

Lead asset Paltusotine is an oral, selective, non-peptide, somatostatin receptor type 2 (SST2) agonist. An alternative to injectable broad spectrum somatostatin analogs, paltusotine is a non ...

Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, ...

Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) ...

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

The CAR product co-expresses a protein, called somatostatin receptor 2, which allows clinicians to monitor the therapy’s effectiveness with a specialized positron emission tomography (PET ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.02%, which has investors questioning if this is right time ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.